Santoleri, Fiorenzo;
Auriemma, Luigia;
Spacone, Antonella;
Marinari, Stefano;
Esposito, Fabio;
De Vita, Francesco;
Petragnani, Giovanni;
Di Fabio, Caterina;
Di Fabio, Letizia;
Costantini, Alberto
Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis
Contributor:
Santoleri, Fiorenzo;
Auriemma, Luigia;
Spacone, Antonella;
Marinari, Stefano;
Esposito, Fabio;
De Vita, Francesco;
Petragnani, Giovanni;
Di Fabio, Caterina;
Di Fabio, Letizia;
Costantini, Alberto
Published:
SAGE Publications, 2022
Published in:
Journal of Pharmacy Practice, 35 (2022) 6, Seite 853-858
Language:
English
DOI:
10.1177/08971900211008625
ISSN:
0897-1900;
1531-1937
Origination:
Footnote:
Description:
Background: In the treatment of idiopathic pulmonary fibrosis (IPF), nintedanib and pirfenidone, with their different mechanisms of action, lead to a reduction in the rate of progression of the fibrosis process measured by the reduction of functional decline, and, in particular, the decrease in forced vital capacity (FVC) and of the diffusion capacity of the lungs for carbon monoxide (DLCO). The objective of this study was to analyze real-life adherence, persistence and efficacy in the use of pirfenidone and nintedanib in the treatment of IPF. Methods: A non-interventional multicenter retrospective observational pharmacological study in real-life treat-ment at 1 and 2 years was conducted. Furthermore, we analyzed the levels of FVC and DLCO at 6 and 12 months, respectively, from the start of treatment. Results: We identified 144 patients in the period between January 2013 and April 2019. From the point of view of adherence, there is no difference between the two drugs, even though patients who used pirfenidone had increasingly higher values: 0.90 vs 0.89, in the first year, and 0.91 vs 0.84, in the second year. In the first year of treatment, the percentage of persistent patients was 67% and 76%, while in the second year, it dropped to 47% and 53% for pirfenidone and nintedanib, respectively. Conclusion: The stratification of the adherence values as a function of the response to treatment in terms of FVC at 12 months for both study drugs showed that patients with optimal response scored adherence of more than 90%.